Form 4: Tempest Therapeutics Director Geoffrey Nichol Acquires Stock Options

Director Geoffrey Nichol acquired stock options for 16,000 shares of Tempest Therapeutics, Inc. at an exercise price of $3.03 on June 13, 2024.

Summary

• Geoffrey Nichol, a director of Tempest Therapeutics, Inc., acquired stock options to purchase 16,000 shares of common stock on June 13, 2024.
• The exercise price for these options is $3.03 per share.
• The options vest fully on the earlier of June 13, 2025, or the date of the Issuer's 2025 annual stockholder meeting, contingent upon continuous service.
• Following the transaction, Nichol directly owns 16,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon Geoffrey Nichol's continuous service with Tempest Therapeutics through the vesting date, indicating an incentive for continued involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates